A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Tadalafil for Duchenne Muscular Dystrophy
Phase of Trial: Phase III
Latest Information Update: 11 Oct 2019
Price : $35 *
At a glance
- Drugs Tadalafil (Primary)
- Indications Duchenne muscular dystrophy
- Focus Registrational; Therapeutic Use
- Sponsors Eli Lilly and Company
- 25 Feb 2016 Planned End Date changed from 1 Apr 2018 to 1 Mar 2016 as reported by ClinicalTrials.gov record.
- 10 Feb 2016 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
- 22 Apr 2015 Planned End Date changed from 1 Dec 2016 to 1 Apr 2018 as reported by ClinicalTrials.gov record.